Risedronate increases bone mineral density and reduces the vertebral fracture incidence in postmenopausal women.
Reginster
J Y
JY
Bone and Cartilage Metabolism Unit, University of Liège, 45 Quai Godefroid Kurth, 4020 Liège, Belgium.
D000368:Aged; D015519:Bone Density / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D000068296:Risedronic Acid; D016103:Spinal Fractures / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*
D002121:Calcium Channel Blockers; D000068296:Risedronic Acid; D012968:Etidronic Acid